Skip to content
DataLookout
Menu

PulseSmartNCT06272981

A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS

StatusCompleted
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

  1. Notable Results posted: Nov 17, 2026
  • Notable: the plan changed

Endpoints

Primary

Number of Participants With Primary Adverse Events (PAEs)
Timeframe: Up to 12 Months post ablation procedure on Day 0
Percentage of Participants With Freedom From Documented (Symptomatic and Asymptomatic) Atrial Arrhythmia (Atrial Fibrillation [AF], Atrial Tachycardia [AT] or Atrial Flutter [AFL]) Episodes Based on Electrocardiographic Data and From All Failure Modes
Timeframe: From Day 91 up to Day 365 post ablation procedure on Day 0

Secondary (1)

Change From Baseline in Atrial Fibrillation Effect on Quality of Life (AFEQT) Total Score at Month 12

Arms and interventions

Pulsed Field (PF)/Radiofrequency (RF) Ablation SystemExperimental

Participants with drug refractory symptomatic PAF who are candidates for atrial fibrillation ablation uses PF and RF energy to produce targeted intracardiac lesions for the treatment of atrial fibrillation.

Devices: Pulsed Field (PF) /Radiofrequency (RF) Catheter ablation

Sites

7 sites in 2 countries

Canada 4, Australia 3